|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 21.05 SEK | +14.40% |
|
+38.49% | -6.86% |
| 23/06 | Citadel Back as Public Short Seller in Synact Pharma | FW |
| 18/06 | Edison Maintains Its Valuation for Synact Pharma After Trial Results | FW |
| Market Cap | 112.02Cr 12Cr 10Cr 9.34Cr 8.71Cr 16Cr 1.09TCr 17Cr 43Cr 539.25Cr 43Cr 42Cr 1.88TCr | P/E 2026 * |
-14.1x | P/E 2027 * | -27.7x |
|---|---|---|---|---|---|
| Enterprise Value | 110.27Cr 11Cr 9.96Cr 9.19Cr 8.57Cr 16Cr 1.08TCr 16Cr 43Cr 530.83Cr 43Cr 42Cr 1.85TCr | EV / Sales 2026 * |
7.95x | EV / Sales 2027 * | 54.1x |
| Free-Float |
70.28% | Yield 2026 * |
-
| Yield 2027 * | - |
Last Transcript: SynAct Pharma AB
| 1 day | +14.40% | ||
| 1 week | +38.49% | ||
| 1 month | +20.84% | ||
| 3 months | +15.15% | ||
| 6 months | -6.86% | ||
| Current year | -6.86% |
| 1 week | 14.5 |  | 22.25 |
| 1 month | 7.05 | | 22.25 |
| Current year | 7.05 | | 24.4 |
| 1 year | 7.05 | | 25.3 |
| 3 years | 4.98 | | 124.6 |
| 5 years | 4.98 | | 146 |
| 10 years | 4.75 | | 146 |
| Manager | Title | Age | Since |
|---|---|---|---|
Jeppe Øvlesen
CEO | Chief Executive Officer | 64 | 01/01/2014 |
Ann Kristin Led
DFI | Director of Finance/CFO | - | 01/03/2026 |
Kirsten Harting
CTO | Chief Tech/Sci/R&D Officer | - | 15/02/2024 |
| Director | Title | Age | Since |
|---|---|---|---|
Jeppe Øvlesen
BRD | Director/Board Member | 64 | 20/03/2024 |
Anders Kronborg
CHM | Chairman | 62 | 20/03/2024 |
Sten Scheibye
BRD | Director/Board Member | 74 | 20/03/2024 |
| Date | Insider | Type | Main position | Quantity | % Market Cap. | |
|---|---|---|---|---|---|---|
| 10/03 | Buy | Chairman | 2,750 | 0.0052% | ||
| 09/03 | Buy | Executive/Senior Manager | 1,500 | 0.0028% | ||
| 09/03 | Quantass ApS
| Buy | Company | 7,900 | 0.0148% |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | +14.40% | +38.49% | +9.86% | -71.71% | 12Cr | |
| -2.48% | +8.34% | +53.87% | +155.75% | 1,07000Cr | |
| -1.76% | +6.23% | +66.27% | +53.44% | 61TCr | |
| -1.05% | +7.19% | +35.57% | +86.77% | 44TCr | |
| +0.83% | +4.18% | +31.11% | +23.88% | 33TCr | |
| -1.38% | +3.75% | +39.33% | +25.04% | 29TCr | |
| +0.30% | +2.56% | +31.62% | +40.64% | 29TCr | |
| -0.10% | +2.23% | -28.43% | -42.77% | 21TCr | |
| +0.44% | +4.35% | +29.69% | +63.10% | 20TCr | |
| +0.01% | +1.03% | +13.95% | +63.93% | 16TCr | |
| Average | +0.95% | +8.39% | +28.28% | +39.81% | 35.96TCr | |
| Weighted average by Cap. | -1.11% | +6.67% | +40.76% | +77.26% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 14Cr 1.43Cr 1.25Cr 1.16Cr 1.08Cr 2.03Cr 135.36Cr 2.07Cr 5.39Cr 67Cr 5.38Cr 5.26Cr 232.7Cr | 2.12Cr 21.82L 19.1L 17.63L 16.45L 30.99L 21Cr 31.54L 82.11L 10Cr 81.99L 80.15L 35Cr |
| Net income | 5.22Cr 53.83L 47.12L 43.5L 40.57L 76.45L 51Cr 77.82L 2.03Cr 25Cr 2.02Cr 1.98Cr 88Cr | -2.6Cr -26.87L -23.52L -21.71L -20.25L -38.16L -25Cr -38.84L -1.01Cr -13Cr -1.01Cr -98.71L -44Cr |
| Net Debt | -1.75Cr -18.04L -15.79L -14.57L -13.59L -25.61L -17Cr -26.07L -67.86L -8.41Cr -67.76L -66.25L -29Cr | 2.49Cr 25.65L 22.45L 20.73L 19.33L 36.43L 24Cr 37.08L 96.51L 12Cr 96.37L 94.21L 42Cr |
Employees
8
Sector
Pharmaceuticals
Calendar
| Date | Price | Change | Volume |
|---|---|---|---|
| 30/26/30 | SEK 21.05 | +14.40% | 8,23,897 |
| 29/26/29 | SEK 18.40 | +19.17% | 6,05,579 |
| 26/26/26 | SEK 15.44 | +0.92% | 1,89,143 |
| 25/26/25 | SEK 15.30 | +1.59% | 2,56,366 |
| 24/26/24 | SEK 15.06 | -0.92% | 2,65,235 |
Quarterly revenue - Rate of surprise
- Stock Market
- Stocks
- SYNACT Stock
Select your edition
All financial news and data tailored to specific country editions
